Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Österborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G, Kaplan P, Steurer M, Schuh A, Montillo M, Kryachok I, Middeke JM, Kulyaba Y, Rekhtman G, Gorczyca M, Daly S, Chang CN, Lisby S, Gupta I. Österborg A, et al. Among authors: rekhtman g. Leuk Lymphoma. 2016 Sep;57(9):2037-46. doi: 10.3109/10428194.2015.1122783. Epub 2016 Jan 19. Leuk Lymphoma. 2016. PMID: 26784000 Clinical Trial.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Gorczyca MM, Carey JL, Chang CN, Lisby S, Gupta IV, Grosicki S. Robak T, et al. Among authors: rekhtman g. Leuk Lymphoma. 2017 May;58(5):1084-1093. doi: 10.1080/10428194.2016.1233536. Epub 2016 Oct 12. Leuk Lymphoma. 2017. PMID: 27731748 Clinical Trial.
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Chang CN, Bal V, Lisby S, Gupta IV, Grosicki S. Robak T, et al. Among authors: rekhtman g. Leuk Lymphoma. 2017 Jul;58(7):1598-1606. doi: 10.1080/10428194.2016.1253837. Epub 2016 Nov 10. Leuk Lymphoma. 2017. PMID: 27830957
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
Miklos U, Strugov V, Lewerin C, Grosicki S, Mazur G, Steurer M, Montillo M, Kryachok I, Middeke JM, Rekhtman G, Stefanelli T, Vincent G, Govindaraju S, Österborg A. Miklos U, et al. Among authors: rekhtman g. Br J Haematol. 2020 May;189(4):689-693. doi: 10.1111/bjh.16429. Epub 2020 Jan 28. Br J Haematol. 2020. PMID: 31994178 Free article. Clinical Trial.
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Grosicki S, Lech-Maranda E, Govind Babu K, Rybka J, Litvinskaya E, Loscertales J, Kriachok I, Kłoczko J, Rekhtman G, Homenda W, Blonski J, Stefanelli T, Vincent G, Banerjee H, Robak T. Grosicki S, et al. Among authors: rekhtman g. Leuk Lymphoma. 2020 Jul;61(7):1748-1751. doi: 10.1080/10428194.2020.1732960. Epub 2020 Feb 28. Leuk Lymphoma. 2020. PMID: 32107948 No abstract available.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
[The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].
Parovichnikova EN, Savchenko VG, Isaev VG, Sokolov AN, Kulikov SM, Kliasova GA, Ryzhko VV, Kravchenko SK, Khoroshko ND, Konstantinova TS, Zagoskina TP, Ziuzgin IS, Rekhtman GB, Moskov VI, Sokolova IV, Anchukova LV, Lapin VA, Loginov AB, Tumakov VA, Korobkin AV, Miliutina GI, Samoĭlova OS, Mal'tsev VI, Pristupa AS, Men'shakova SN, Domnikova NP, Gavrilova LV, Obidina NA, Porokhina OV, Kaplanov KD, Medvedeva LI, Khuazheva NK, Pilipenko GI, Golubeva ME, Maksimov AG, Ploskikh MA, Khlevnaia NV. Parovichnikova EN, et al. Among authors: rekhtman gb. Ter Arkh. 2007;79(7):14-9. Ter Arkh. 2007. PMID: 17802784 Clinical Trial. Russian.
28 results